Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Joel L Johnson"'
Autor:
Joel L Johnson, Yi Shi, Rose Snipes, Salim Janmohamed, Timothy E Rolfe, Bill Davis, Anthony Postle, Colin H Macphee
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e89034 (2014)
The aim of this study was to assess the effects of darapladib, a selective oral investigational lipoprotein-associated phospholipase A2 inhibitor, on both plasma and plaque lipoprotein-associated phospholipase A2 activity.Patients undergoing elective
Externí odkaz:
https://doaj.org/article/4f6a0d57773b45c8a3130070c50f8fba
Autor:
Michael H. Davidson, Darapladib Investigators, Andrew Zalewski, Luis M. Ruilope, Markolf Hanefeld, Emile R. Mohler, Christie M. Ballantyne, Joel L. Johnson
Publikováno v:
Journal of the American College of Cardiology. 51:1632-1641
Objectives This study examined the effects of darapladib, a selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, on biomarkers of cardiovascular (CV) risk. Background Elevated Lp-PLA2 levels are associated with an increased risk of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12cf84e5bbf603f3a116bc0515d154e4
https://doi.org/10.1016/j.jacc.2007.11.079
https://doi.org/10.1016/j.jacc.2007.11.079
Autor:
Salim Janmohamed, Bill Davis, Colin H. Macphee, Anthony D. Postle, Rose Snipes, Joel L. Johnson, Yi Shi, Timothy E. Rolfe
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e89034 (2014)
PLoS ONE
PLoS ONE
BackgroundThe aim of this study was to assess the effects of darapladib, a selective oral investigational lipoprotein-associated phospholipase A2 inhibitor, on both plasma and plaque lipoprotein-associated phospholipase A2 activity.MethodsPatients un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2d2a2f2921f420a55ed5205db9334ae
http://europepmc.org/articles/PMC3930668?pdf=render
http://europepmc.org/articles/PMC3930668?pdf=render
Autor:
Joel L. Johnson
Publikováno v:
The ANNALS of the American Academy of Political and Social Science. 535:110-121
When a government acquires a product from foreign sources, some financial transaction must occur. Countries may pay cash, borrow funds to pay for the goods over time, provide other goods in return, or receive the goods on a grant basis. With respect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf9ef68debe1420fd782e91081b6bf1d
https://doi.org/10.1177/0002716294535001008
https://doi.org/10.1177/0002716294535001008
Autor:
Douglas Weaver, Elizabeth Tarka, Michelle L. O'Donoghue, Joel L. Johnson, Mary Ann Lukas, Patrick W. Serruys, Ph. Gabriel Steg, Eugene Braunwald, Aldo P. Maggioni, Christoph Bode, Harvey D. White, Judith S. Hochman, Greg Cicconetti, Christopher P. Cannon
Publikováno v:
American heart journal. 162(4)
Background Higher levels of lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) are associated with a higher risk of cardiovascular events and may play a causal role in atherogenesis. Darapladib inhibits Lp-PLA 2 activity in plasma and in arterial p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddaf631ae13429eade4fce86c3fcd0fa
https://pubmed.ncbi.nlm.nih.gov/21982651
https://pubmed.ncbi.nlm.nih.gov/21982651
Autor:
Denise Lawrence, Elizabeth Tarka, Emile R. Mohler, Jeffrey S. Berger, Andrew A. Zalewski, Joel L. Johnson, Trupti Trivedi, Michael H. Davidson, Christie M. Ballantyne
Publikováno v:
American heart journal. 161(5)
Subjects with peripheral artery disease (PAD) are at increased risk of cardiovascular morbidity and mortality, perhaps in part, related to increased levels of inflammation, platelet activity, and lipids. We therefore sought to investigate the relatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::968da43fdacbe3c0aefc05e79bfca09a
https://pubmed.ncbi.nlm.nih.gov/21570531
https://pubmed.ncbi.nlm.nih.gov/21570531
Autor:
Emile R, Mohler, Christie M, Ballantyne, Michael H, Davidson, Markolf, Hanefeld, Luis M, Ruilope, Joel L, Johnson, Andrew, Zalewski
Publikováno v:
Journal of the American College of Cardiology. 51(17)
This study examined the effects of darapladib, a selective lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor, on biomarkers of cardiovascular (CV) risk.Elevated Lp-PLA(2) levels are associated with an increased risk of CV events.Coronar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::485096829383f9afeebbd10a5e2e9cfc
https://pubmed.ncbi.nlm.nih.gov/18436115
https://pubmed.ncbi.nlm.nih.gov/18436115